Literature DB >> 3872603

Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography.

A Wolkin, J Jaeger, J D Brodie, A P Wolf, J Fowler, J Rotrosen, F Gomez-Mont, R Cancro.   

Abstract

Local cerebral metabolic rates were determined by positron emission tomography and the deoxyglucose method in a group of 10 chronic schizophrenic subjects before and after somatic treatment and in eight normal subjects. Before treatment, schizophrenic subjects had markedly lower absolute metabolic activity than did normal controls in both frontal and temporal regions and a trend toward relative hyperactivity in the basal ganglia area. After treatment, their metabolic rates approached those seen in normal subjects in nearly all regions except frontal. Persistence of diminished frontal metabolism was manifested as significant relative hypofrontality. These findings suggest specific loci of aberrant cerebral functioning in chronic schizophrenia and the utility of positron emission tomography in characterizing these abnormalities.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872603     DOI: 10.1176/ajp.142.5.564

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  26 in total

Review 1.  Functional brain mapping of psychopathology.

Authors:  G D Honey; P C Fletcher; E T Bullmore
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 2.  Neuropsychiatric rehabilitation for persistent mental illness.

Authors:  J Jaeger; E Douglas
Journal:  Psychiatr Q       Date:  1992

Review 3.  Structural and functional brain imaging in schizophrenia.

Authors:  J M Cleghorn; R B Zipursky; S J List
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

5.  A Comprehensive Analysis of Nuclear-Encoded Mitochondrial Genes in Schizophrenia.

Authors:  Vanessa F Gonçalves; Carolina Cappi; Christian M Hagen; Adolfo Sequeira; Marquis P Vawter; Andriy Derkach; Clement C Zai; Paula L Hedley; Jonas Bybjerg-Grauholm; Jennie G Pouget; Ari B Cuperfain; Patrick F Sullivan; Michael Christiansen; James L Kennedy; Lei Sun
Journal:  Biol Psychiatry       Date:  2018-03-15       Impact factor: 13.382

6.  Proteomics as a tool for understanding schizophrenia.

Authors:  Daniel Martins-de-Souza
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-12-31       Impact factor: 2.582

Review 7.  Mitochondrial dysfunction in schizophrenia: an evolutionary perspective.

Authors:  Vanessa F Gonçalves; Ana C Andreazza; James L Kennedy
Journal:  Hum Genet       Date:  2014-10-14       Impact factor: 4.132

8.  Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study.

Authors:  M Soyka; W Koch; H J Möller; T Rüther; K Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-18       Impact factor: 5.270

9.  Diminished cerebral metabolic response to motor stimulation in schizophrenics: a PET study.

Authors:  W Guenther; J D Brodie; E J Bartlett; S L Dewey; F A Henn; N D Volkow; K Alper; A Wolkin; R Cancro; A P Wolf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

10.  The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.